Electrical Design and Automation Engineer
About the job
- A degree in Automation Engineering, Electrical Engineering, Computer Science, Mechatronics, or a comparable qualification.
- Experience developing industrial control and automation systems.
- Strong programmable logic controller programming skills, ideally with Beckhoff TwinCAT and EtherCAT.
- Experience with complex software and automation systems.
- Knowledge of communication protocols such as OPC Unified Architecture and Transmission Control Protocol/Internet Protocol.
- Structured and methodical approach, strong teamwork skills, and excellent German and English language skills.
- Willingness to travel occasionally.
- Develop programmable logic controller and automation solutions using Beckhoff TwinCAT for complex machine platforms.
- Contribute to the design and evolution of the automation and software architecture of extreme ultraviolet systems.
- Integrate sensors, actuators, drive systems, and other subsystems.
- Implement communication interfaces such as OPC Unified Architecture and Transmission Control Protocol/Internet Protocol.
- Work closely with systems engineering, electrical engineering, software, and mechanical engineering teams.
- Support testing, commissioning, and fault analysis.
- Develop and improve development, testing, and simulation methods.
- Work in agile development teams and take technical ownership of work packages.
- Experience with C#/.NET, Azure DevOps, continuous integration and continuous delivery, simulation, or virtual commissioning.
About the company
Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS SMT opened its Korea Innovation Center in July 2026, deepening customer access.
- July 24, 2026 capacity expansion adds 25,000 square meters in Oberkochen.
- ASML expects 2027 EUV output growth, with Zeiss optics capacity already expanding.
What critics are saying
- ASML bought €4.41 billion from Zeiss in 2025; customer concentration is extreme.
- A prolonged Oberkochen outage would halt ASML production within months.
- Monument Peak sued Zeiss on February 6, 2026 over Kodak patents.
What makes Zeiss unique
- ZEISS SMT remains ASML's sole EUV optics supplier in 2026.
- Oberkochen and Wetzlar are the only places building ASML optical columns.
- High-NA EUV optics from ZEISS anchor sub-2nm lithography for Intel and TSMC.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.
ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.
ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.